Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
January 05, 2017 09:05 ET
|
Ocera Therapeutics, Inc.
Data Support Feasibility of Oral OCR-002 as Maintenance Therapy for Patients with Hepatic Encephalopathy Company Plans to Initiate Phase 2a in H1 2017 with New Optimized Tablet Formulation PALO...